Pms20 Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis in Biologic-Experienced Patients From the Portuguese Perspective

Abstract

The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs. Methods: A Cost of Illness model was developed to estimate the average cost per year sustained by the NHS and Social Security Sistem in Italy. A Systematic Literature Review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalization costs were calculated considering the administrative database of Hospitalization available in Italy between 2008-2016. Data were extrapolated considering ICD9-CM 733.0 (Osteoporosis) in the primary or secondary diagnosis of each hospitalization. Costs were estimated considering the DRG national tariff associated with each hospitalisation. Finally, the administrative databases of the National Social Security Institute (INPS) (2009-2015) were analysed for the estimate the pension and disability costs from the social perspective. Results: The model estimated an average annual economic burden of osteoporosis in Italy of V 2.2 billion. Of these cost, 79% (V 1.7 billion) was associated to hospitalizations, 17% (V 0.35 billion) for pharmacological treatments, 3% (V 0.07 billion) to outpatients visits, and 1% (V 0.01 billion) to social security costs. The average yearly cost per patient was equal to V 17.557 (V 8.706 for hospitalizations). Analysing severe patients, hospitalization costs increase to V 12,159 (+40% if compared to general osteoporosis patients). Conclusions: The analysis showed that osteoporosis represents one of the main health problems in Italy and the ability to maintain patients in a non-severe health state could decrease the economic burden from both NHS and social perspective.